Cases & Deals

The Regents of the University of California establishes patent portfolio related to anti-CD22 antibodies for the treatment of B cell malignancies

Clients Regents of the University of California, The

Jones Day assisted the Regents of the University of California in the development of a global patent portfolio related to uses of CD22 antibodies for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL).